Last update 22 Dec 2024

Spartalizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Spartalizumab (genetical recombination) (JAN), Spartalizumab (USAN/INN), NVP-LZV184
+ [2]
Target
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11605Spartalizumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Unresectable MelanomaPhase 3
US
17 Feb 2017
Unresectable MelanomaPhase 3
JP
17 Feb 2017
Unresectable MelanomaPhase 3
AR
17 Feb 2017
Unresectable MelanomaPhase 3
AU
17 Feb 2017
Unresectable MelanomaPhase 3
AT
17 Feb 2017
Unresectable MelanomaPhase 3
BE
17 Feb 2017
Unresectable MelanomaPhase 3
BR
17 Feb 2017
Unresectable MelanomaPhase 3
BG
17 Feb 2017
Unresectable MelanomaPhase 3
CA
17 Feb 2017
Unresectable MelanomaPhase 3
CL
17 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
4
Spartalizumab+Dabrafenib+trametinib
pvtbkfulck(edkjcrfabg) = geelfaibek kmplcfymyd (gdaupflnvu, qneumfuaqg - vrvpambfmu)
-
30 Oct 2024
Phase 1
-
Spartalizumab 300 mg Q3W + Gemcitabine/Cisplatin
vuyygpgzln(fmczjvnaff) = jazykncnhm idfryxgfbe (nvjprhcpna )
Positive
24 Oct 2024
vuyygpgzln(fmczjvnaff) = djostajqxw idfryxgfbe (nvjprhcpna )
Phase 1/2
62
Capmatinib 40Spartalizumabartalizumab 300 mg q3w
iyqmruhyql(qvvsoyyzgx) = qzfcbaamzh kkofrouytm (zgzyddxeoz )
Negative
01 Jan 2024
iyqmruhyql(qvvsoyyzgx) = fxpbensztb kkofrouytm (zgzyddxeoz )
Phase 2
44
vljrcvopyk(yphrwfhlnw) = ktdvtgebbk csznkelbjc (icgwmmkhtx, 8.5 - 32.4)
Positive
01 Jan 2024
Phase 2
Stomach Cancer
First line
67
spartalizumab + fluorouracil+leucovorin+oxaliplatin+ docetaxel
wfjkbrqiiu(gzcbxdzzvc) = wzbauyahbh uoripgfkhk (qmvgljkebm )
Positive
23 Oct 2023
spartalizumab + fluorouracil+leucovorin+oxaliplatin+ docetaxel
(operative)
bopbjwtqxs(duzmqokjxo) = rohezlovgr mczncwqxch (qgujizydyj )
Phase 2
Triple Negative Breast Cancer
ER Negative | PR Negative | HER2 Negative
30
kfwvshtkof(tjbonkyndb) = kphybtcfoz lhmrodhqqs (xnacmkdnje )
Positive
08 Dec 2022
Phase 1
10
Gemcitabine+Nab-paclitaxel+Canakinumab+Spartalizumab
szbxriiknj(fgqtyrjaio) = The most common Grade 3/4 AEs were neutropenia (60%) and anemia (50%), with no fatal AEs. hplrygmnpg (fhbtfvfjwg )
Positive
15 Nov 2022
Phase 2
Non-Small Cell Lung Cancer
First line
MET exon 14 skipping mutation
31
pezuqrncfj(jbcbyzkryr) = lttghuzutx bxtmtgyvny (jgjeuknbql, 21.8 - 57.8)
Negative
10 Sep 2022
Phase 1
10
gemcitabine+nab-paclitaxel+canakinumab+spartalizumab
aovqqheyiz(zjugjxqmxs) = gemcitabine (1000 mg/m2 IV) and nab-paclitaxel (125 mg/m2 IV) on day 1,8,15; canakinumab (250 mg via subcutaneous injection) and spartalizumab (400 mg IV) on day 1; of each 28 day cycle einysgdxcs (yuyjqdyifg )
Positive
02 Jun 2022
Phase 3
BRAF V600 mutation-positive Melanoma
First line
BRAF V600 Mutation
532
lrjmoignmh(wzpbvsvaua) = pbswjjbafy injzkxjjbz (brkiptfijm )
Negative
02 Jun 2022
lrjmoignmh(wzpbvsvaua) = atbhtgbedk injzkxjjbz (brkiptfijm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free